Efficacy of addition of the anti-inflammatory, IV glutathione to standard ketamine IV therapy in major depressive disorder

What Was Tested

This randomized controlled trial paper looks at Glutathione.

This double-blind study with 30 patients divided into 2 groups of 15 each, aimed to determine if GSH, added to standard ketamine infusion (GSH+K), rendered better outcomes in MDD patients versus patients receiving ketamine infusions with a normal saline placebo (K+NS).

Why It Was Studied

Ketamine, a N-methyl-D-aspartate (NMDA) antagonist, is used for treatment-resistant depression (TRD).

Who Took Part

According to the abstract, 30 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Glutathione study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Glutathione.

The comparison arm used a placebo, so changes seen with Glutathione could be set against what happens without it.

The timeline in the abstract includes 14 days.

What Was Measured

The subject headings attached to it are Ketamine, Major Depressive Disorder, Glutathione, Antidepressive Agents, Anti-Inflammatory Agents, Depressive Disorder, Treatment-Resistant and Psychiatric Status Rating Scales.

The authors tagged it with the keywords Depression, Inflammation, Neuroplasticity, Oxidative stress and Treatment-resistant depression.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glutathione in 30 patients over 14 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (Psychiatry research), a journal based in Ireland.

More context: the Glutathione compound page, all human trials.